These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 17951625)

  • 1. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids.
    Chuchalin A; Jacques L; Frith L
    Clin Drug Investig; 2008; 28(3):169-81. PubMed ID: 18266402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
    Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison.
    Boonsawat W; Goryachkina L; Jacques L; Frith L
    Clin Drug Investig; 2008; 28(2):101-11. PubMed ID: 18211118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
    Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
    Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
    Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
    Jenkins CR; Jones PW; Calverley PM; Celli B; Anderson JA; Ferguson GT; Yates JC; Willits LR; Vestbo J
    Respir Res; 2009 Jun; 10(1):59. PubMed ID: 19566934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.
    Bourbeau J; Christodoulopoulos P; Maltais F; Yamauchi Y; Olivenstein R; Hamid Q
    Thorax; 2007 Nov; 62(11):938-43. PubMed ID: 17557771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
    N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
    Lapperre TS; Snoeck-Stroband JB; Gosman MM; Jansen DF; van Schadewijk A; Thiadens HA; Vonk JM; Boezen HM; Ten Hacken NH; Sont JK; Rabe KF; Kerstjens HA; Hiemstra PS; Timens W; Postma DS; Sterk PJ;
    Ann Intern Med; 2009 Oct; 151(8):517-27. PubMed ID: 19841453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
    Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.